Page 68 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

Mean OS, month 18.1±2.6 16.4±2.6 19.1±2.6 0.857

Median PFS, month 8.1 (0.9-25.2) 10.3 (0.9-25.2) 6.4 (1.8-23.8) 0.150
Response rate, %

CR 13.6 14.3 12.5 0.906
PR 27.3 14.3 50 0.703

SD 31.8 42.9 12.5 0.124
PD 27.3 28.6 25 0.856

DCR, % 72.7 71.4 75 0.856
AFP decline, n (%) 11 (64.7%) 7 (63.6) 4 (66.7) 0.900

irAE 2 (9.1) 1 (7.1) 1 (12.5) 0.679
Statistics presented as median (range), mean ± standard deviation or number

(percent).
# Recent R/T is defined as the interval between R/T and Nivolumab treatment less

than one month or concurrent.
AFP decline is defined as 10 % reduction of AFP after 2 months of Nivolumab

treatment.
Abbreviations: R/T, radiation therapy; HBV, hepatitis B virus; HCV, hepatitis C virus;

NA, not applicable; ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer;
MVI, macrovascular invasion; EHS, extra-hepatic spread; AFP, alpha-fetoprotein;

SBRT, stereotactic body radiation therapy; OS, overall survival; PFS, progression-free
survival; CR, complete remission; PR, partial remission; SD, stable disease; PD,

disease progression; DCR, disease control rate; irAE, immune-related adverse event.